Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2008

View Archived Issues

Novel acronycine derivatives with in vivo antitumor activity

Spider toxin shows potential to alleviate mechanical pain

Promising activity of GTI-2040 in combination with AraC in acute myeloid leukemia

New treatments for obesity disclosed in recent patent literature

Novel anti-HIV agents patented by Roche and Bayer

Recent Aska patent describes novel agents for urinary disorders

CYT003-QbG10 monotherapy was safe and effective in phase II allergic disease studiey

Icagen completes phase I multiple ascending dose trial of senicapoc

OrthoLogic initiates dosing in AZX-100 phase I dermal/hypertrophic scarring trial

Sosei completes phase III NorLevo trial in emergency contraception

ValiRx acquires global rights to VAL-201 for prostate cancer

Ortho Biotech returns Japanese rights for Yondelis to PharmaMar

IND submitted on behalf of Generex for immunotherapy vaccine trial

Genmab completes recruitment in phase II ofatumumab study in CLL

Novartis plans to acquire remaining shares in Speedel Holding

Calistoga initiates phase I clinical trial of PI3K delta inhibitor CAL-101

VIA Pharmaceuticals completes patient visits in phase II CEA trial of VIA-2291

CV Therapeutics receives E.U. marketing authorization for ranolazine

Compugen has reported positive results from an in vivo study of CGEN-25007

FDA approves NeuroSearch's IND application for ACR-16 in Huntington's disease

Ardea moves RDEA-806 into phase IIa proof-of-concept study for gout

Access signs merger agreement to Acquire MacroChem

Preemptive treatment reduces skin toxicities in patients treated with panitumumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...